Back to Results

Protagenic Therapeutics (PTIX)

Protagenic Therapeutics, Inc. is a healthcare company focused on biotechnology research and the development of medicines based on cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in Santa Barbara, California. Its common stock is listed on OTC Markets under the symbol PTIX. As an ordinary equity security, the listing represents ownership interest in Protagenic Therapeutics rather than a fund, debt instrument, or other specialized security.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-PTIX
$0.71
-22.4% Downside
Overvalued
Not available
Not available
Fair
0.0%
November 19, 2026
0.2x
0.8x
1.655 M
753.656 K
0.0%
95.0%
-6.9
-36.7%
Valuation • Fair Value

Protagenic Therapeutics (OTC-PTIX) Fair Value by Valuation Model

Review the available estimates for Protagenic Therapeutics (OTC-PTIX), including Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.71

Estimated downside of 22.4% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$33.48

Classic Ben Graham valuation formula reference.

Comps Fair Value

$0.71

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for Protagenic Therapeutics (OTC-PTIX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Protagenic Therapeutics (OTC-PTIX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-4.212 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Protagenic Therapeutics (OTC-PTIX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Protagenic Therapeutics (OTC-PTIX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Altman Z-Score

-6.9

Lower score that deserves closer risk review.

FCF / Net Income

-36.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Protagenic Therapeutics (OTC-PTIX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Protagenic Therapeutics (OTC-PTIX)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 19, 2026

Days to Earnings

62

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Protagenic Therapeutics (OTC-PTIX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Protagenic Therapeutics (OTC-PTIX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Protagenic Therapeutics (OTC-PTIX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Protagenic Therapeutics (OTC-PTIX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Protagenic Therapeutics (OTC-PTIX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Protagenic Therapeutics (OTC-PTIX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Protagenic Therapeutics (OTC-PTIX) Stock FAQ

Data-supported answers about Protagenic Therapeutics (OTC-PTIX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.71
Estimated downside 22.4%
Valuation Rating
Overvalued
Estimated downside of 22.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Protagenic Therapeutics (OTC-PTIX) is $0.71. This implies an estimated downside of 22.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 22.4% versus the current market price.

The current financial health read for Protagenic Therapeutics (OTC-PTIX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Protagenic Therapeutics (OTC-PTIX) is November 19, 2026.

The latest available data indicates no current dividend yield for Protagenic Therapeutics (OTC-PTIX).

The current P/E ratio listed for Protagenic Therapeutics (OTC-PTIX) is 0.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Protagenic Therapeutics is 1.655 M.

The current enterprise value listed for Protagenic Therapeutics is 753.656 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Protagenic Therapeutics is OTC-PTIX, and the stock is listed on OTC Markets.

Protagenic Therapeutics (OTC-PTIX) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Protagenic Therapeutics is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Protagenic Therapeutics is 95.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B